Home » MEMORY TO START TRIAL OF ALZHEIMER'S DRUG
MEMORY TO START TRIAL OF ALZHEIMER'S DRUG
Memory Pharmaceuticals has announced that it will begin a Phase IIa clinical trial of MEM 3454 for Alzheimer's disease.
MEM 3454 was safe and well-tolerated in Phase I trials, including treatment with 450 mg dosages during the single-ascending-dose portion of the trial program. The drug was also safe and generally well-tolerated with 150 mg dosages in the multiple-ascending-dose portion of the program.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May